Clinical Trial Update: A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD [Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 2 randomized, double-masked trial evaluating intravitreal KH902 for neovascular age-related macular degeneration.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• KH902

Snippet

Sponsor: Chengdu Kanghong Biotech Co., Ltd. | Conditions: Neovascular Age-related Macular Degeneration | Phase 2 | Status: COMPLETED